AU2016276704A1 - Formulations for neoplasia vaccines and methods of preparing them - Google Patents

Formulations for neoplasia vaccines and methods of preparing them Download PDF

Info

Publication number
AU2016276704A1
AU2016276704A1 AU2016276704A AU2016276704A AU2016276704A1 AU 2016276704 A1 AU2016276704 A1 AU 2016276704A1 AU 2016276704 A AU2016276704 A AU 2016276704A AU 2016276704 A AU2016276704 A AU 2016276704A AU 2016276704 A1 AU2016276704 A1 AU 2016276704A1
Authority
AU
Australia
Prior art keywords
hydro
peptide
neo
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016276704A
Other languages
English (en)
Inventor
Edward F. Fritsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Original Assignee
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc filed Critical Broad Institute Inc
Publication of AU2016276704A1 publication Critical patent/AU2016276704A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2016276704A 2015-06-09 2016-06-09 Formulations for neoplasia vaccines and methods of preparing them Abandoned AU2016276704A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562172890P 2015-06-09 2015-06-09
US62/172,890 2015-06-09
PCT/US2016/036605 WO2016201049A2 (en) 2015-06-09 2016-06-09 Formulations for neoplasia vaccines and methods of preparing thereof

Publications (1)

Publication Number Publication Date
AU2016276704A1 true AU2016276704A1 (en) 2017-12-14

Family

ID=56236097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016276704A Abandoned AU2016276704A1 (en) 2015-06-09 2016-06-09 Formulations for neoplasia vaccines and methods of preparing them

Country Status (19)

Country Link
US (1) US20190060428A1 (cg-RX-API-DMAC7.html)
EP (1) EP3307303A2 (cg-RX-API-DMAC7.html)
JP (2) JP2018521028A (cg-RX-API-DMAC7.html)
KR (1) KR20180016531A (cg-RX-API-DMAC7.html)
CN (1) CN107921107A (cg-RX-API-DMAC7.html)
AU (1) AU2016276704A1 (cg-RX-API-DMAC7.html)
CA (1) CA2988135A1 (cg-RX-API-DMAC7.html)
CL (2) CL2017003151A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017012893A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180015A (cg-RX-API-DMAC7.html)
EC (1) ECSP18001613A (cg-RX-API-DMAC7.html)
HK (2) HK1252325A1 (cg-RX-API-DMAC7.html)
IL (1) IL256173A (cg-RX-API-DMAC7.html)
MX (1) MX2017015881A (cg-RX-API-DMAC7.html)
PE (1) PE20180601A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502233A1 (cg-RX-API-DMAC7.html)
RU (2) RU2753246C2 (cg-RX-API-DMAC7.html)
TW (2) TW202241500A (cg-RX-API-DMAC7.html)
WO (1) WO2016201049A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3023788T3 (da) 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7334124B2 (ja) * 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
KR102416048B1 (ko) 2017-10-16 2022-07-04 일루미나, 인코포레이티드 변이체 분류를 위한 심층 컨볼루션 신경망
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
WO2019204663A1 (en) * 2018-04-19 2019-10-24 Neon Therapeutics, Inc. Peptide formulations and uses thereof
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
WO2020131586A2 (en) * 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
EP3937973A1 (en) * 2019-03-11 2022-01-19 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
JP2022551086A (ja) * 2019-10-03 2022-12-07 ヴィトルヴィア ホールディングス インコーポレイテッド 結合組織修復の方法
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
CN113461805B (zh) * 2021-09-02 2021-12-10 广州吉妮欧生物科技有限公司 一种嵌入抗原表位肽的荧光素酶及其构建方法和应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3056782B2 (ja) 1989-11-03 2000-06-26 ヴァンダービルト ユニバーシティ 標的器官内での遺伝子の発現用医薬組成物
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
AU1588092A (en) 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
AU725143B2 (en) 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
ES2312344T3 (es) 1999-05-28 2009-03-01 Targeted Genetics Corporation Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf.
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
CN1291012C (zh) 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 修饰的安卡拉牛痘病毒(mva)的变株
PT1335987E (pt) 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AU2003239805B2 (en) 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CA2533581C (en) 2003-07-24 2012-05-08 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
RU2285548C2 (ru) * 2004-10-25 2006-10-20 Георгий Цыренович Дамбаев Способ лечения онкозаболеваний
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DK2131857T3 (en) * 2007-03-22 2015-09-14 Univ Colorado Regents A method of producing an immunologically active adjuvansbundet dried vaccine composition
EP2225002A4 (en) 2007-12-31 2011-06-22 Nanocor Therapeutics Inc RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES
DK3023788T3 (da) * 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
LT3473267T (lt) * 2011-05-24 2021-11-25 BioNTech SE Individualizuotos vakcinos nuo vėžio
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
EP3076992B1 (en) * 2013-12-06 2022-04-06 The Broad Institute, Inc. Formulations for neoplasia vaccines

Also Published As

Publication number Publication date
CA2988135A1 (en) 2016-12-15
JP2021152053A (ja) 2021-09-30
CR20180015A (es) 2018-03-20
JP2018521028A (ja) 2018-08-02
PE20180601A1 (es) 2018-04-09
HK1252325A1 (zh) 2019-05-24
RU2017145963A (ru) 2019-07-16
KR20180016531A (ko) 2018-02-14
TWI750122B (zh) 2021-12-21
CN107921107A (zh) 2018-04-17
US20190060428A1 (en) 2019-02-28
CL2017003151A1 (es) 2018-04-06
RU2021122284A (ru) 2021-10-21
ECSP18001613A (es) 2018-05-31
PH12017502233A1 (en) 2018-06-25
IL256173A (en) 2018-02-28
TW202241500A (zh) 2022-11-01
TW201718000A (zh) 2017-06-01
CO2017012893A2 (es) 2018-05-21
RU2753246C2 (ru) 2021-08-12
HK1253271A1 (zh) 2019-06-14
RU2017145963A3 (cg-RX-API-DMAC7.html) 2019-07-17
WO2016201049A2 (en) 2016-12-15
EP3307303A2 (en) 2018-04-18
WO2016201049A3 (en) 2017-02-09
CL2019003264A1 (es) 2020-02-14
MX2017015881A (es) 2018-04-18

Similar Documents

Publication Publication Date Title
US20250312458A1 (en) Formulations for neoplasia vaccines
US20230190896A1 (en) Combination therapy with neoantigen vaccine
RU2753246C2 (ru) Составы вакцин против неоплазии и способы их получения
HK40081228A (en) Formulations for neoplasia vaccines
HK1228249B (en) Formulations for neoplasia vaccines
HK1228249A1 (en) Formulations for neoplasia vaccines

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted